SIOUX FALLS, SD – November 04, 2025 – PRESSADVANTAGE – Glaucoma remains one of the leading causes of blindness in the United States, often progressing silently until vision loss has already occurred.

About 3 million people in the United States have glaucoma, and it’s the second leading cause of blindness worldwide, according to the Centers for Disease Control and Prevention. While there is no cure ...

Glaucoma creeps in without pain or obvious symptoms, slowly damaging your optic nerve. Regular eye exams and early detection are the only ways to prevent permanent vision loss and keep your sight safe ...

Glaucoma is the term for a group of eye conditions that damage the optic nerve at the back of the eye. Without treatment, it can lead to vision loss and blindness. Glaucoma is not a life threatening ...

More than 3 million Americans have glaucoma, but only half are aware they have the eye condition. Glaucoma, the second leading cause of blindness, is caused by damage to the optic nerve. The vision ...

Scientists at Mizzou have identified two small molecules, agmatine and thiamine, that could both reveal and fight glaucoma.

Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and even blindness. About 3 million Americans have glaucoma. It is the second leading cause of blindness ...

More than 3 million Americans have glaucoma, and man y of them are seniors older than 65. Approximately 75% of people who are legally blind because of glaucoma are seniors, in fact. And it is believed ...

Notice things seem a little blurrier lately? While some degree of vision change over the years is normal, there are many things you can do to ward off more serious eye troubles like cataracts, ...

An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored ...

Using an experimental gene therapy, Harvard scientists have successfully restored vision to mice suffering glaucoma by effectively rewinding the aging process in their cells. While still in the early ...